Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
15.72
+0.61 (4.04%)
At close: Mar 9, 2026, 4:00 PM EDT
15.95
+0.23 (1.46%)
After-hours: Mar 9, 2026, 5:00 PM EDT
Summit Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Operating Revenue | - | - | - | 0.71 | 1.81 | |
| Revenue | - | - | - | 0.71 | 1.81 | |
| Revenue Growth (YoY) | - | - | - | -61.03% | 110.35% | |
| Gross Profit | - | - | - | 0.71 | 1.81 | |
| Selling, General & Admin | 556.75 | 60.21 | 29.26 | 26.74 | 23.61 | |
| Research & Development | 537.67 | 150.78 | 59.47 | 52 | 85.35 | |
| Other Operating Expenses | - | - | - | -14.42 | -20.97 | |
| Operating Expenses | 1,094 | 210.99 | 88.74 | 64.33 | 88 | |
| Operating Income | -1,094 | -210.99 | -88.74 | -63.62 | -86.19 | |
| Interest Expense | - | -8.69 | -16.46 | -4.4 | -0.24 | |
| Interest & Investment Income | 15.5 | 13.47 | 10.4 | 1.51 | - | |
| Currency Exchange Gain (Loss) | -0.61 | -0.1 | 1.03 | -4.11 | -2.14 | |
| Other Non Operating Income (Expenses) | -0.05 | - | -0.25 | 0.3 | -0.04 | |
| EBT Excluding Unusual Items | -1,080 | -206.31 | -94.01 | -70.31 | -88.6 | |
| Asset Writedown | - | - | - | -8.47 | - | |
| Pretax Income | -1,080 | -221.32 | -614.93 | -78.78 | -88.6 | |
| Net Income | -1,080 | -221.32 | -614.93 | -78.78 | -88.6 | |
| Net Income to Common | -1,080 | -221.32 | -614.93 | -78.78 | -88.6 | |
| Shares Outstanding (Basic) | 748 | 719 | 620 | 193 | 92 | |
| Shares Outstanding (Diluted) | 748 | 719 | 620 | 193 | 92 | |
| Shares Change (YoY) | 4.06% | 15.96% | 220.50% | 109.60% | 32.67% | |
| EPS (Basic) | -1.44 | -0.31 | -0.99 | -0.41 | -0.96 | |
| EPS (Diluted) | -1.44 | -0.31 | -0.99 | -0.41 | -0.96 | |
| Free Cash Flow | -323.59 | -142.25 | -76.89 | -42.21 | -72.89 | |
| Free Cash Flow Per Share | -0.43 | -0.20 | -0.12 | -0.22 | -0.79 | |
| Gross Margin | - | - | - | 100.00% | 100.00% | |
| Operating Margin | - | - | - | -9024.25% | -4764.29% | |
| Profit Margin | - | - | - | -11174.75% | -4897.84% | |
| Free Cash Flow Margin | - | - | - | -5986.67% | -4029.46% | |
| EBITDA | -1,094 | -210.9 | -88.54 | -62.36 | -84.84 | |
| D&A For EBITDA | 0.15 | 0.09 | 0.2 | 1.26 | 1.35 | |
| EBIT | -1,094 | -210.99 | -88.74 | -63.62 | -86.19 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.